References:
1. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for
SARS-CoV-2. JAMA. 2020;323(22):2249-2251.
2. Kaltsas A, Sepkowitz K. Community acquired respiratory and
gastrointestinal viral infections: challenges in the immunocompromised
host. Curr Opin Infect Dis. 2012;25(4):423-430.
3. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2
infection: a nationwide analysis in China. Lancet Oncol.2020;21(3):335-337.
4. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More
Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19
Outbreak. Cancer Discov. 2020;10(6):783-791.
5. Millen GC, Arnold R, Cazier JB, et al. Severity of COVID-19 in
children with cancer: Report from the United Kingdom Paediatric
Coronavirus Cancer Monitoring Project. Br J Cancer.2021;124(4):754-759.
6. Bisogno G, Provenzi M, Zama D, et al. Clinical Characteristics and
Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in
Italian Pediatric Oncology Patients: A Study From the Infectious
Diseases Working Group of the Associazione Italiana di Oncologia e
Ematologia Pediatrica. J Pediatric Infect Dis Soc.2020;9(5):530-534.
7. Cleto-Yamane TL, Rodrigues-Santos G, de Magalhaes-Barbosa MC, et al.
Screening of COVID-19 in outpatient children with cancer or solid organ
transplantation: preliminary report. Eur J Pediatr. 2021.
8. Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ.
COVID-19 in immunocompromised patients: A systematic review of cancer,
hematopoietic cell and solid organ transplant patients. J Infect.2021;82(3):329-338.
9. El Dannan H, Al Hassani M, Ramsi M. Clinical course of COVID-19 among
immunocompromised children: a clinical case series. BMJ Case Rep.2020;13(10).
10. Peacock TP, Penrice-Randal R, Hiscox JA, Barclay WS. SARS-CoV-2 one
year on: evidence for ongoing viral adaptation. J Gen Virol.2021;102(4).
11. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during
treatment of chronic infection. Nature. 2021;592(7853):277-282.
12. Mansi L, Spehner L, Daguindau E, et al. Study of the
SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer
patients. Eur J Cancer. 2021;150:1-9.
13. Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in
recipients of hematopoietic cell transplantation. J Clin Invest.2020;130(12):6656-6667.
14. U.S. Food and Drug Administration. (2020). Xpert Xpress
SARS-CoV-2/Flu/RSV: Instructions for use
https://www.fda.gov/media/142438/download. Accessed Accessed May
6, 2021.
15. U.S. Food and Drug Administration (2020). BioFire Respiratory Panel
2.1 (RP2.1): Instructions for use fda/gov/media/137583/download.
Accessed Accessed May 6, 2021.
16. Perera R, Tso E, Tsang OTY, et al. SARS-CoV-2 Virus Culture and
Subgenomic RNA for Respiratory Specimens from Patients with Mild
Coronavirus Disease. Emerg Infect Dis. 2020;26(11):2701-2704.
17. Epstein RL SH, Hofman M, Lodi S, White LF, Barocas JA, Bouton TC,
Xiao Y, et al. . Time to SARS-CoV-2 PCR clearance in immunocompromising
conditions: is test-based removal from isolation necessary in severely
immunocompromised individuals? Open Forum Infectious Diseases.2021;ofab164.
18. Qin W, Bai W, Liu K, et al. Clinical Course and Risk Factors of
Disease Deterioration in Critically Ill Patients with COVID-19.Hum Gene Ther. 2021;32(5-6):310-315.
19. Calvet J, Gratacos J, Amengual MJ, et al. CD4 and CD8 Lymphocyte
Counts as Surrogate Early Markers for Progression in SARS-CoV-2
Pneumonia: A Prospective Study. Viruses. 2020;12(11).
20. Truong TT, Ryutov A, Pandey U, et al. Increased viral variants in
children and young adults with impaired humoral immunity and persistent
SARS-CoV-2 infection: A consecutive case series. EBioMedicine.2021;67:103355.